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1. Introduction 
By definition, dementia is an acquired global impairment in memory, 
personality and intellect in an alert patient, that is sufficiently severe 
to interfere with social and/or occupational functioning. In the 
absence of a stroke or rapidly growing cerebral tumours (among 
other causes), the onset is usually gradual and the cognitive decline 
is always progressive. In the absence of a cure for the disease, non-
pharmacological inventions and the judicious use of pharmacotherapy 
may not only help the patient and alleviate the stress on the caregiver, 
but can also help in delaying institutionalisation. 
1.1 Prevalence and burden of disease
The worldwide prevalence of dementia currently approximates 
35.6 million people, a figure set to rise to 65.7 million by 2030 and (by 
doubling every 20 years) to 115.4 million by 2050. Nearly two-thirds 
of individuals with dementia live in developing countries, where the 
sharpest increase in numbers is said to occur.[1] The prevalence of 
dementia is approximately 5 - 7% of the elderly population. Starting at 
1% for 60-year-olds, the prevalence doubles every 5.1 years, rising to 
some 30 - 45% of those aged 85 and older[2,3] in developed countries, 
while doubling every 7 years in developing countries.[4] Among 
the South African elderly an estimate would place the number of 
dementia sufferers at 250 000, with some 35 000 of these suffering 
from Alzheimer’s disease (AD). 
Twenty per cent of AD patients are alive after a 15-year period, the 
mean duration of illness being some 10 - 12 years.[5] Of the people with 
late-onset (65 years and older) dementia in developed countries, more 
than half have AD, some 15% have vascular dementia (VaD), and 
the remaining 30%, a variety of some 60 other forms of dementia. [6] 
Many cases of AD exhibit a confluence with cerebrovascular disease 
(CvD).[7] The total worldwide societal cost of dementia was estimated 
at US$ 422 billion in 2009, which included US$142 billion (34%) for 
informal care.[8] Americans estimate that dementia costs them some 
US$100 billion per year,[1] and yet a delay in the onset of AD by 
only 5 years would halve the prevalence of the disease, resulting in 
enormous savings of human misery and cost to society.[5,9] In all cases 
there are profound psychosocial effects on the caregiver, in whom 
the rates of depression, substance abuse, hospitalisation and physical 
illness are all increased.[9] 
1.2 Causes and types of dementia
In the South African population, dementia due to the HIV/AIDS 
complex (affecting mainly the younger age group) is the most 
common. Among the elderly the most prevalent is VaD, followed by 
AD, which is on the increase.[7] 
1.2.1 Alzheimer’s disease 
The neuropathological hallmarks of AD are amyloid plaques, 
neurofibrillary tangles, and synaptic and neuronal loss with 
subsequent brain atrophy. Macroscopically, and with neuro-imaging 
(magnetic resonance imaging (MRI) and computed tomography 
(CT) scan), this demonstrates as flattening of gyri, widening of sulci, 
atrophied medial temporal lobes and enlarged ventricles. Pathology at 
microvascular level has increasingly been implicated in the aetiology 
of AD, blurring the boundaries with VaD in many cases. AD and 
possibly most other dementias tend to follow a sinusoidal course 
in that the initial slow, progressive deterioration accelerates rapidly 
before flattening out towards the end – in keeping with the 3 stages of 
mild, moderate and severe.[10] 
The duration of illness may be as short as 6 months or as long 
as 20 years, with an average of 12 years. Neurochemically there are 
deficits in neurotransmitters including acetylcholine, noradrenaline, 
serotonin, and somatostatin. Specific mutations on chromosomes 
21, 14 and 1, inherited as familial autosomal dominant traits with 
full penetrance, are found in some 1% of all AD patients. Here the 
illness usually presents itself in the 40s or early 50s and is essentially 
‘pre-senile’ in onset (i.e. before the age of 65 years). More than 90% 
of cases of AD occur in individuals older than 60 years. Individuals 
carrying one or both alleles coding for apolipoprotein E-4 (APOE4) 
on chromosome 19 bear an elevated risk for late-onset AD, although 
this gene is not itself a cause of the disorder.[11] Fig. 1 represents the 
course of AD.
1.2.2 Vascular dementia – with or without stroke
Among the VaDs, multi-infarct dementia associated with multiple 
areas of cortical infarction, patchy cognitive impairment, focal 
neurological signs and a ‘stepwise’ rather than a steady, continuous 
deterioration as in AD is more easily diagnosed than dementia due to 
vascular damage of the deep white matter. 
After each shower of ‘mini strokes’, which produce a sudden 
deterioration in the individual’s functioning, there is a partial recovery 
which stabilises within approximately 3 - 12 weeks until the next 
stroke or ‘step’ occurs several weeks or months later. It is hypothesised 
that in both vascular and alcohol-induced dementias, temporary 
vascular spasms may result in intermittent or fluctuating intellectual 
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Fig. 1. Course of Alzheimer’s disease (with/out memory enhancer).[10]
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and personality changes, with unpredictable bouts of irritability and 
mood swings. In all types of VaDs the risk factors for stroke such as 
hypertension, arrhythmias, hypercholesterolaemia, diabetes, smoking 
and alcohol need to be assessed. Fig. 2 represents the course of multi-
infarct dementia compared to AD.
1.2.3 Combination of Alzheimer’s disease and vascular dementia
This is referred to as AD with CvD.
1.2.4 Dementia with Lewy bodies 
Dementia with Lewy bodies usually exhibits as fluctuations in 
cognition (mimicking a sub-acute delirium) with pronounced 
variation in attention and alertness, recurrent well-formed visual 
hallucinations (especially sun-downing), and motor features 
of Parkinsonism. The course of the illness tends to be rapidly 
progressive, interspersed with repeated falls, syncope, transient loss of 
consciousness, other hallucinations and congruent delusions. These 
patients tend to be sensitive to the side-effects of neuroleptic agents 
(requiring utilisation of drugs like clozapine or newer neuroleptic 
agents). They may be responsive to cholinesterase inhibitors.
1.2.5 Pick’s disease and frontotemporal dementia 
Pick’s disease (PD) is a progressive dementia that chiefly affects the 
frontal cortex. PD most commonly manifests between the ages of 50 
and 60 years and is distinguished from frontotemporal dementia by the 
presence of characteristic intraneuronal argentophilic Pick inclusion 
bodies found at autopsy. Patients present with prominent personality 
changes and impaired executive function. In frontotemporal dementia 
diagnostic criteria range across 4 domains: 
1. Behavioural disorder: insidious onset and slow progression; early 
loss of personal and social awareness; early signs of disinhibition; 
mental rigidity and inflexibility; and hyperorality, stereotyped and 
perseverative behaviour. 
2. Affective symptoms: depression and anxiety; somatic preoccupation; 
emotional unconcern. 
3. Speech disorder: reduction and stereotypy of speech; echolalia and 
perseveration. 
4. Physical signs: early primitive reflexes and incontinence; late 
akinesia, rigidity and tremor.
1.2.6 Substance-induced persisting dementia
Paramount are deep white-matter changes blurred with alcohol-
induced vasculopathy, clinically often indistinguishable from VaDs 
and with the same risk factors as precipitating and perpetuating 
causes. Note that both vascular and alcohol-induced dementia 
patients have relatively well-preserved personalities, compared to 
the degree of dementia present. Their excellent social skills or verbal 
ability may be misleading unless one screens for dementia using the 
Mini Mental State Examination (MMSE).
1.2.7 Huntington’s disease
Huntington’s disease is an inherited disease (autosomal dominant 
gene on chromosome 4) characterised by degeneration of the basal 
ganglia and cerebral cortex. Age of onset is between 15 and 50 years 
,when choreiform movements and progressive dementia are noted. 
The dementia initially presents as a sub-cortical dementia before 
affecting the cortex as the illness progresses. No cure is currently 
available and death results within 15 - 20 years. Psychiatric disorders, 
especially depression, may be the presenting feature.
1.2.8 Parkinson’s disease 
The primary features are tremor, muscular rigidity, hypokinesia and 
postural abnormality. Although a movement disorder, cognitive 
impairment occurs in 10 - 40% of patients during the course of the 
disease, known as Parkinson’s disease dementia. 
1.2.9 Creutzfeldt-Jakob’s disease 
Creutzfeldt-Jakob’s disease is brought about by a virus-like infective 
agent called a prion. It causes a rapid progressive dementia also 
affecting the pyramidal and extrapyramidal systems. A new variant of 
Creutzfeldt-Jakob’s disease, described in England in 1995, appears to 
express itself under certain conditions in individuals under the age of 
40 years, leading to death within a year. This variant is associated with 
bovine spongiform encephalopathy or ‘mad cow disease’. 
1.2.10 Dementia associated with normal pressure hydrocephalus 
Normal pressure hydrocephalus occurs in the elderly and is 
characterised by a triad of ataxia (wide-based, shuffling gait), urinary 
incontinence and dementia. CT  scans of the brain show prominent 
enlargement of the ventricles out of keeping with the widening of the 
sulci. Ventricular peritoneal shunts may improve cognitive functions 
in 10 - 30% of patients. Usually a demented person only becomes 
incontinent on attaining an MMSE score of 8 - 10/30.
1.2.11 Dementia secondary to head injury
This is lesion-location- and severity-specific, and diagnosed and 
treated accordingly. It may manifest with 2 distinct symptom clusters, 
namely cognitive impairment (i.e. decreased information processing 
speed, decreased attention, increased distractibility) and behavioural 
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Fig. 2. Course of (a) Alzheimer’s disease and (b) vascular dementia.10
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disturbances. The behavioural disturbances may involve personality 
changes, impulsivity and depression, all of which can be exacerbated 
by substance misuse.
1.2.12 AIDS dementia complex/HIV dementia
HIV infection currently affects 5 million people in South Africa and is 
set to reach a steady state of 32% within less than a decade. The course 
of the illness may vary considerably but in general the patient converts 
to AIDS after 9 years of illness and dies a year later from systemic 
complications. Nearly 90% of AIDS brains are histopathologically 
abnormal, more than half of them uniquely due to HIV infection. 
Referred to as the AIDS dementia complex, this condition contributes 
significantly to the morbidity of HIV patients, causing varying degrees 
of cognitive, motor or behavioural impairment, known as HIV-
associated neurocognitive disorders (HAND).
1.2.13 Other less common causes of dementia
• Endocrine states (hypo- or hyperthyroidism, hyperparathyroidism)
• Deficiency states (B complex vitamins)
• Intracranial space-occupying lesions (subdural haematomas, 
tumours)
• Post-irradiation dementia
• Demyelinating disorders
• Neurosyphilis
2. Diagnosis, clinical characteristics and course
The diagnostic criteria for AD are outlined in Table 1.[11] 
Clinical features include the following: 
• Memory impairment: Poor memory must interfere with daily 
functioning. Initially, short-term memory is affected, with the later 
involvement of long-term memory. 
• Personality and behavioural changes: Emotions are shallow and 
easily influenced by environmental factors; irritability and bouts 
of anger are common. Usually premorbid traits become more 
accentuated. There is a loss of initiative and the person becomes 
increasingly apathetic and withdrawn. Emotional blunting ensues, 
and may be mistaken for depression.
• Intellectual impairment: Thinking becomes more concrete. There 
are word-finding and other language difficulties (dysphasia), the 
person may no longer recognise familiar faces or objects (agnosia) 
and may be unable to carry out simple manual tasks such as 
fixing a plug or dressing themselves (apraxia). A key feature is the 
instrumental impairment of activities of daily living (e.g. ability to 
use telephone, shop, handle finances). 
• Physical changes: As the disease progresses, the patient appears 
unduly frail and weak, is stooped in posture with slow, shuffling 
gait and mild tremor of the hands. There is weight loss, regardless 
of appetite, increasing bouts of restlessness and confusion, and 
reduced sphincter control.
2.1 Course
This may give an indication of aetiology. Patients with vascular 
(especially multi-infarct) dementia and to some extent alcohol-
induced dementia will present with patchy memory loss and 
fluctuating disturbances in language and behaviour with a relatively 
well-preserved personality in the earlier phases, characterised by 
appropriate social interaction.
• A step-wise deterioration rather than a steady even pattern
• A more abrupt deterioration rather than slow, insidious onset
• Attacks of dizziness, frequent falls and fainting spells, nocturnal 
confusion
• Bouts of urinary urgency, particularly at night.
Table 1. Diagnostic criteria for dementia of the Alzheimer’s type[11]* 
A. The development of multiple cognitive deficits manifested by both:
1. Memory impairment (impaired ability to learn new information or to recall previously learned information)
2. One (or more) of the following cognitive disturbances:
a. aphasia (language disturbance)
b. apraxia (impaired ability to carry out motor activities despite intact motor function)
c. agnosia (failure to recognise or identify objects despite intact sensory function)
d. disturbance in executive functioning (i.e., planning, organising, sequencing, abstracting)
B.  The cognitive deficits in criteria A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline 
from a previous level of functioning.
C. The course is characterised by gradual onset and continuing cognitive decline.
D. The cognitive deficits in criteria A1 and A2 are not due to any of the following: 
 1. Other central nervous system conditions that cause progressive deficits in memory and cognition (e.g. cerebrovascular disease, Parkinson’s disease, 
Huntington’s disease, subdural hematoma, normal-pressure hydrocephalus, brain tumour)
 2. Systemic conditions that are known to cause dementia (e.g. hypothryoidism, vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcaemia, neurosyphyllis, HIV infection)
3. Substance-induced conditions
E. The deficits do not occur exclusively during the course of a delirium.
F. The disturbance is not better accounted for by another Axis I disorder (e.g. major depressive disorder, schizophrenia).
*Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright © 2000). American Psychiatric Association. For educational purposes 
only.
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3. Assessment and differential diagnosis
3.1 Mild cognitive impairment 
Of note is that up to one-quarter of elderly present as ‘doddery’, falling 
into the realm of mild cognitive impairment (MCI), also known as 
age-associated cognitive decline. Here the MMSE score is around 
27/30. Cognitive function is not impaired to the point where it 
interferes significantly with daily social or occupational functioning, 
but may well do so over the next 2 - 5 years, when an estimated 30% of 
this category are known to go on to exhibit dementia. These patients 
need to be re-evaluated at regular intervals.
3.2 Depression and delirium
At this stage of diagnostic screening dementia must be distinguished 
from depression (primarily a mood disorder with very little 
disturbance in cognition), and delirium (a transient organic disorder 
hallmarked by a global cognitive impairment as well as disturbance in 
consciousness and attention/concentration deficit). In addition there 
is a reversal of the sleep-wake cycle. In the elderly, depression and 
delirium may frequently coexist with AD or herald its presence, and 
both require management in their own right. Delirium constitutes 
a medical emergency. Good collateral information from a reliable 
family member, friend or caregiver is crucial. A detailed history and 
thorough physical examination including blood (‘organic work-up’) 
and urine tests not only distinguish AD from depression and delirium, 
but also help to differentiate AD from other types of dementia. A 
review of all current prescribed medications and over-the-counter 
preparations, with particular emphasis on those impacting on central 
nervous system functions, is essential.
3.3 Assessment of neuropsychiatric symptoms
This is discussed below. 
3.3.1 Cognitive assessment: the Mini Mental State Examination
Ascertain the degree of cognitive impairment by administering 
the MMSE,[12] which was designed to distinguish dementia from 
depressive pseudodementia. While one or two mistakes are allowed, 
the nature of these mistakes is of importance (e.g. an accountant 
failing to do the serial sevens). An MMSE score of 27 generally 
indicates MCI. In mild AD (MMSE range 21 - 26) there is short-term 
memory impairment, often accompanied by symptoms of anxiety 
and depression. Moderate AD (MMSE range 11 - 20) is characterised 
by neuropsychiatric phenomena such as visual hallucinations, false 
beliefs, restlessness and disturbed sleep patterns. Severe AD (MMSE 
range 0 - 10) is characterised by prominent cognitive decline, motor 
signs and the onset of loss of sphincter control.   
While depressed patients will still obtain a high MMSE score, an 
MMSE score of 26 or less out of 30 is strongly indicative of dementia, 
where the patient has had at least 7 years of schooling. AD patients 
lose on average some 2 - 3 points on the MMSE per year, and progress 
can thus be tracked by re-administration of the test at 3 - 6-monthly 
intervals. There is no time limit for the completion of the test. 
Note that a person with dementia may achieve an MMSE score of 
30 out of 30 with some difficulty, while still holding a high position in 
working life. This function is support-staff dependent. 
3.3.2 Functional assessment: activities of daily living
Cognition and behaviour also impact on the patient’s level of 
function.[13] This determines whether patients can still perform more 
complicated tasks such as taking their medication, difficult household 
chores, shopping, cooking and finances (instrumental activities of 
daily living  (IADL)) or only wash, dress, feed and toilet themselves 
(basic activities of daily living (BADL)).[14] The watershed between 
IADL and BADL usually occurs at an MMSE of 16 out of 30,[15] while 
urinary incontinence occurs at a score of around 8. 
3.3.2.1 Driving
Driving a car relies on implicit memory, praxis and executive 
functioning. In the early stages of the illness patients can still drive a car 
because these abilities are still relatively intact. With time, however, they 
are unable to pay attention to all aspects of driving and often become 
impulsive or exercise the wrong options. Note that if the dementia 
renders the person incapable of driving and controlling a vehicle safely, 
he/she is medicolegally disqualified from driving. Doctors have a legal 
obligation under the National Road Traffic Act 1996 (Act 93 of 1996) to 
report such individuals to the traffic authorities.[16] 
In general:
• Assess all cases on individual merit.
• Patients must drive in conditions affording good visibility and 
then in day time only, on non-busy suburban roads and always 
accompanied by a caregiver.
• Their MMSE should be at least 20-22/30 or above and they must 
still be able to do the pentagon test (which tests for visuospatial 
ability) or trail-making B.
• Re-assess at 3-monthly intervals.
3.3.2.2 Firearms
Similarly gun licenses should be revoked for the same reasons.
3.3.2.3 Financial affairs and wills
Should the patient be incapable of handling her/his own financial 
affairs, urge a reliable and trustworthy member of the family to take 
control of the situation. Transfer of authority by means of power 
of attorney works well in early dementia where competency is still 
preserved. Failing this, or where no family members are available, 
curatorship should be sought. The forms are obtainable from the court 
who will appoint a curator bonis to attend to the patient’s affairs based 
on the recommendations of a psychiatrist and medical officer/general 
practitioner. Social workers and occupational therapists who are well-
versed in these matters may have to be called in for advice and help 
with these cases. A patient who has not yet written a will or testament 
but now wishes to do so should be referred to a psychiatrist in order to 
establish testamentary capacity.[16] 
3.3.2.4 Social assessment
A thorough social evaluation is of the utmost importance when 
assessing a dementia patient. The social assessment includes 
information regarding where the person lives, living circumstances, 
relevant family members and caregivers, and the extent of coping of 
both patient and caregivers, employment (if relevant) and economic 
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resources, and degree of additional social support, as well as 
medicolegal matters.
3.3.2.5 Elder abuse
Awareness of abuse in the area of financial resources and the 
administration of the patient’s affairs is of paramount importance. 
It should be determined who draws, administers and dispenses the 
patient’s financial resources and pension. 
Elder abuse includes physical abuse as well as ‘acts of omission’ 
or negligence leading to the detriment of the health and well-being 
of the person. This would include physical, psychological, financial 
and material aspects. Examples would be the denial of food, visits, 
medication, clothing and other essentials. Note that sexual abuse and 
incest also occur. 
Cases must be reported to Halt Elder Abuse Line (toll free 0800 
003081) for investigation and management.
3.4 Comorbid medical conditions
Patients with dementia commonly have comorbid medical conditions 
such as depression, cardiovascular and pulmonary diseases, infections, 
arthritis, sleep disturbances, falls, incontinence and drug-related 
adverse events, among others. There is a strong association between 
medical conditions and impaired cognition in AD.[17] 
People with dementia, particularly those who live alone, are at risk 
of inadequate nutrition and dehydration. Both of these factors can 
contribute to the development of neuropsychiatric symptoms (NPS). 
The propensity to develop subsequent bronchopneumonia or urinary 
tract infection is very high.
Comorbid medical conditions need to be optimally managed, 
especially vascular risk factors which may be contributing to the 
dementia by exacerbating any vascular disease. Regular medication 
review is mandatory as is the supervision of medication by a 
responsible caregiver.
3.5 Investigations
Cost restraints and other practicalities often dictate the number 
of investigations that can be performed. Generally, in a typical or 
advanced case of dementia, investigations have little to offer towards 
treatment. A ‘positive’ result is more likely to be obtained when:
• The patient is less than 65 years of age
• Onset has been recent and the course rapid
• Course of disease fluctuates markedly
• Physical examination reveals a neurological deficit.
Special investigations help to improve or rule out treatable contributory 
and exacerbating causes of dementia. The full ‘organic work-up’ entails 
a full blood count, plasma viscosity, urea and electrolytes; thyroid, 
liver and parathyroid function tests, random blood sugar, niacin, 
vitamin B12, red cell folate and lipogram. C-reactive protein (CRP) 
levels may be indicated. Additional tests include syphilis serology, 
HIV and urine dipstick (this also helps to exclude a concurrent 
urinary tract infection). 
More specialised investigations encompass a CT or MRI scan (with 
measurements of the medial temporal lobes) as well as psychometric 
testing. Single photon-emission CT results often settle diagnostic 
speculation. 
Assessment by a trained neuropsychologist may be required when the 
cognitive impairment is very mild or does not conform to an expected 
pattern. 
The trimmed-down version of the ‘organic work-up’ consists of the 
following only: haemoglobin, mean cell volume, white cell count and 
platelets; glucose; potassium, sodium and urea/creatinine; thyroid-
stimulating hormone; albumin and gamma-glutamyl transferase 
(γGT); calcium; vitamin B12; total cholesterol; syphilis serology and 
urine dipsticks.[10] 
4. Treatment 
Patients with dementia almost invariably display neuropsychiatric 
symptoms (NPS), such as disturbances in mood with psychotic 
and vegetative symptoms among other phenomena.[18] Hitherto the 
focus with cognitive enhancers has been on cognitive improvement, 
overlooking the fact that these medications will often improve the 
NPS, especially in the early phases of the illness. Amelioration of these 
symptoms may be insufficient later on, at which stage treatment with 
more conventional psychotropic agents will be required. 
4.1 Treatment goals
• Re-establishing the homeostasis, correcting for both internal and 
external factors by correcting influences such as dehydration, 
urinary tract infection, and disruptions in day/night rhythm.
• Stabilising the NPS to promote patient well-being and reduce 
caregiver burden.
• Maintaining the quality of life and highest level of patient functioning 
for as long as possible, in order to delay institutional care.
4.2 General aspects of treatment
As with the assessment process, treatment is holistic, by its nature 
multifaceted and, more often than not, multidisciplinary. Of necessity, 
the treatment involves caregivers and family. Team-work is essential 
and should utilise as many members from the community (helpful 
family members, religious groups) and medical resources (social 
worker, occupational therapist, community nurse) as possible. Patient 
target symptoms include declining cognition and impairment in 
daily functioning, among various associated symptoms that manifest 
during the course of the disorder. Treatment aims at maximising 
functional performance and quality of life, while reducing the period 
of disability.
4.2.1 Imparting the diagnosis
Ensure that key family members and caregivers are present. Be 
compassionate, honest and leave sufficient time available for questions 
and answers in order to contain the situation. Keep hope alive in 
that there are treatments available for some dementias, and potential 
benefits from psycho-education, social support and medication 
trials. Apart from the diagnosis, include prognosis and management 
strategies. Keep an open-door policy, link up with the family physician 
and refer to the local support organisation.[19] Additional issues that 
need to be addressed include genetics and other practical and medico-
legal decisions such as driving, firearms, power of attorney, financial 
controls, curatorship and wills, and capacity assessments (discussed 
above). Note that the detection of elder abuse, incapacity to drive and/
or ownership of a firearm is notifiable by law.[16] 
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4.2.2 Accommodation and level of supervision
The situation in South Africa mirrors the global move away from 
residential institutions. Fewer beds are available at ever-rising cost. 
Patients, their families and caregivers increasingly have to rely on 
their own resources. To help them in this task are the primary-care 
facilities, social clubs, seniors centres, daycare centres and respite-care 
facilities. Welfare organisations and non-profit organisations (NPOs) 
offering support, counselling and psycho-education are invaluable.
4.3 Pharmacological treatment
4.3.1 Acetylcholinesterase inhibitors and memantine
Based on the cholinergic hypothesis of AD, cognitive deterioration is 
associated with progressive loss of cholinergic neurons and decreasing 
levels of acetylcholine in the brain. Both acetylcholinesterase (AChE) 
and butyrylcholinesterase (BuChE) have been found to play an 
important role in the degradation of acetylcholine. Table 2 outlines 
these medications.
The 3 acetylcholinesterase inhibitors (AChEIs) differ in their 
pharmacological action: donepezil selectively inhibits AChE; 
rivastigmine affects both AChE and BuChE; and galantamine 
selectively inhibits AChE and also affects nicotinic receptors. To 
date, these differences have not been shown to result in differences in 
efficacy and tolerability.[20] 
An alternative strategy is the inhibition of excitotoxic amino-
acid neurotransmitters (e.g. glutamate, aspartate, homocysteine) 
which play an important role in the pathophysiology of dementia. 
Memantine is an N-methyl-D-aspartate receptor antagonist which 
regulates calcium flux across membranes and may protect against 
neuronal death.
A combination of an AChEI with memantine appears to be more 
effective than either agent on its own and is well tolerated, there being 
no pharmacokinetic or pharmacodynamic interactions between the 
two.[20,21]
Most indications for the above agents are AD-specific but may 
also benefit those AD patients with cerebrovascular disease. Other 
indications include MCI, diffuse Lewy body (DLB) dementia, and 
Parkinson’s disease dementia. These indications are, however, country-
specific as is their range of applications for the mild, moderate and 
severe stages of AD. The mode of administration (slow-release capsules, 
transdermal patches) further impacts more positively on tolerability, 
compliance and efficacy; as do ease of titration, price of product and 
familiarity with the medication. Under ideal circumstances, treatment 
should start in the prodromal/symptomatic/MCI phase of AD, bearing 
in mind that patients only tolerate the minimum effective dose in 
the early stages. The earlier diagnosis would involve the testing of 
cerebrospinal fluid biomarkers for AD, which is currently being 
standardised.[22] Patients respond with both improved cognitive and 
behavioural changes. Studies tend not to capture the more subtle 
changes in the dementing patient, such as the return of personality, 
spontaneity, insight and interest in their surroundings. The relief 
in caregiver stress burden is observed immediately, and this in turn 
enhances the well-being of the caregiver. Improvement in the mild to 
moderate AD patient is usually above baseline for the first 9 months; 
then it slowly declines as the illness relentlessly progresses. Data 
obtained at the 3-year mark show that patients are still functioning at 
above their expected level of deterioration when compared to untreated 
patients observed over the past decades.[23,24] With positive results, 
treatment may continue uninterrupted to an MMSE as low as 5/30, 
after which continuing benefit becomes increasingly questionable and 
difficult to evaluate in research;[17,25] or where the patient’s dementia 
has progressed to a stage where there is no significant benefit from 
continued therapy.[26] Furthermore, longer-term follow-up data of 
AD patients on a previous generation AChE shows a cost-saving of 
7.5% over the patient’s lifetime from diagnosis to death.[27,28] Though 
the costs of medical and social services were reduced, most of the 
savings were due to reduced time in nursing home placement (at least 
14 months). New treatments that can both improve clinical outcomes 
and save costs should be given serious consideration by clinicians and 
administrators.[29] 
The benefits of treatment with AChEIs are rapidly lost when drug 
administration is interrupted for as little as 6 weeks and may not be 
fully regained when drug treatment is reinstated.[30] Notwithstanding, 
it may be necessary to check whether the medication is having 
the desired effect by very occasionally withholding treatment for 
approximately 2 weeks when the recurrence in severity of former 
NPS/behavioural and psychological symptoms of dementia (BPSD) 
target symptoms will act as an indicator for continued treatment.[26]
At least two-thirds of patients can be expected to derive modest 
benefit from the above medications with regard to not only 
improvement in cognition, but also to NPS/BPSD and activities of 
daily living (ADL). Failure to benefit from one AChEI or memantine 
does not necessarily mean that the patient will not respond to another 
of these medications.[19,20] 
4.3.1.1 Adverse effects
Excess cholinergic stimulation with the use of AChEIs may lead to 
transitory nausea, vomiting, dizziness, insomnia and diarrhoea. A 
lowering of dosage, short pause or even rechallenge (if treatment 
is re-initiated after a prolonged period) is usually successful in 
overcoming these events should they occur. Urinary incontinence, 
abdominal muscle cramps and excessive sweating may occur and 
usually indicate the need for a ‘switch’ to another agent. There appear 
to be no important differences between drugs in respect of type or 
frequency of adverse events.[20] 
AChEIs may potentially have vagotonic effects on heart rate (i.e. 
bradycardia), of importance in patients with ‘sick sinus syndrome’ 
Table 2. Pharmacological treatment schedule for Alzheimer’s 
disease[10]
1. One of the following acetylcholinesterase inhibitors:
Donepezil (Aricept)  5 - 10 mg at night
Rivastigmine (Exelon)   3 - 6 mg twice daily
Galantamine (Reminyl) 16 - 24 mg daily
and/or
2. NMDA receptor antagonist: Memantine (Ebixa) 10 - 20 mg daily. 
3.  Psychotropic agents for residual symptoms, i.e. mood (depression 
and irritability) and behavioural disturbances (restlessness, 
agitation, psychotic symptoms, insomnia).
4.  Control of cardiovascular risk factors such as hypertension, 
diabetes mellitus, dyslipidaemia and smoking.
NMDA - N-methyl-D-aspartate
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or other supraventricular cardiac conduction disturbances such 
as sinoatrial or atrioventricular block. These medications should 
therefore be used with caution in patients with cardiovascular 
disease or those taking concurrent medicines that reduce heart rate. 
Bradycardic drugs include beta-blockers, digoxin, amiodarone and 
calcium channel antagonists. Recent reviews show that the incidence 
of cardiovascular side-effects is low and that serious adverse effects 
are rare. Interestingly, the value of pretreatment screening and routine 
electrocardiograms (ECG) is questionable and these are not currently 
recommended by the National Institute for Health and Clinical 
Excellence.[20,31]
Common (usually transient) side-effects of memantine include 
confusion, dizziness, headache and tiredness. Uncommon are anxiety, 
hypertonia and vomiting. Note that, being an amantadine derivative 
memantine may enhance the action of L-dopa and dopaminergic 
agonists.[20] 
Generally, all the above interact with anticholinergic drugs and 
cholinomimetics to a variable extent.
4.3.1.2 Recommended dosages
It is also important to optimise the dose and duration of cholinesterase 
inhibitor treatment. It is thought that the higher the dose tolerated by 
the patient, the better the result. A minimal trial period of between 3 
and 6 months is indicated. 
AD patients are given a once-daily dose of 5 mg donepezil at 
night, increasing to 10 mg after 4 weeks. Medication is given at 
night to obviate side-effects which may occur 4 hours after ingestion 
coinciding with peak plasma levels. The half-life of donepezil is 70 
hours and steady state is usually obtained in 14 - 21 days. As with 
the other medications, should side-effects become intolerable, one 
skips the medication for a day or two.[20] Elimination of the drug is 
through both renal excretion of intact drug and bio-transformation 
via the cytochrome P450 system. The latter is only partially saturated 
by the drug, and hence drug-drug interactions tend not to be a 
problem. Rivastigmine is initiated at 1.5 mg twice daily, and increased 
by 1.5 mg twice daily every 2 - 4 weeks to a maximum of 12 mg 
daily. Rivastigmine has almost no potential for interaction since 
it is metabolised at the site of action and does not affect hepatic 
cytochromes. Galantamine is initiated at 8 mg daily, and the dose is 
then increased by 8 mg every 4 weeks to a maximum of 24 mg daily. 
Metabolism is via the cytochrome P450 system. Memantine is given in 
the morning with a starting dose of 5 mg, then raised in increments of 
5 mg on a weekly basis to a maximum of 20 mg per day. Metabolism 
is primarily non-hepatic (Table 3).[10,20,32-34]
4.3.1.3 Follow up
It is important to determine the patient’s response to medication, 
and as such it may be useful to complete a scale such as the MMSE or 
ADL[15] or the Neuropsychiatric Inventory (NPI) for NPS[35] in order to 
help quantify the treatment response. 
4.3.1.4 Neuropsychiatric symptoms
NPS, also formally known as BPSD, rather than cognitive decline, 
prompt entry into long-term care. Over 90% of subjects with dementia 
will exhibit at least one NPS that needs specific management at some 
point in the course of their illness.[18,36] These symptoms may wax and 
wane over time while some symptoms (e.g. visual hallucinations in 
DLB dementia) are more common in some dementias than in others. 
Another frequent mistake made by both caregivers and physicians 
alike is to assume that there are no hallucinations or delusions, since 
patients may objectively not display these phenomena which are 
only elicited on very careful mental state examination or behavioural 
assessment. The behavioural domains are best assessed by using the 
NPI.[35] The diffuse nature of the NPS means that each patient needs 
an individual assessment and treatment strategy.[18,32,35-37] 
In general, once treatable medical causes for NPS have been 
addressed or eliminated, psychosocial intervention follows with or 
without psychotropic medication. The latter consists of the use of 
AChEIs or memantine on their own or in combination followed by 
antidepressant, antipsychotic or other medication as indicated.
The general treatment principles follow those for younger adults. 
Except that half to two-thirds of the adult dose is given. ‘Start low, 
go slow, review frequently’ is the standard watchword, as the elderly 
are more sensitive to medication side-effects than the younger adult. 
Note that polypharmacy may be necessary in the form of a non-
sedating (high-potency) neuroleptic by day and a sedating (low-
potency) neuroleptic at night. Psycho-education about the illness and 
supervision of medication is essential, keeping in mind that data on 
medication are, in general, controversial (Table 4).[32,36]
4.3.2 Antidepressants
While symptoms of anxiety or depression are common in the 
premonitory stages of dementia, e.g. their occurrence at 50 years of 
age may herald dementia 10 - 20 years later, once the dementia is 
established, apathy is the most common NPS (frequently misinterpreted 
as ‘depression’).[18] Though major depression may precede the onset of 
AD, it occurs less frequently as the disease progresses, while minor 
depression, mild depressive symptoms or bouts of dysphoria become 
much more common in the early course of AD. If in doubt about the 
coexistence of depression with AD, a trial of antidepressant medication 
should be given. Note that antidepressants also have anxiolytic, and 
in the case of some newer-generation antidepressants, sedating if 
not hypnotic qualities. Symptomatic treatment of neuropsychiatric 
disturbances will afford both the patient and caregiver much relief. By 
and large the elderly require smaller dosages (about half to two-thirds) 
of antidepressant medication than that of the young adult population, 
and in most cases the ‘sedating’ antidepressants are preferred. Higher 
dosages may be required for more resistant cases where the diagnosis 
of coexistent depression is certain. Exercise caution with regard to 
side-effects and patient tolerance. AD patients with an MMSE of 
below 20/30 tend not to benefit from an antidepressant in terms of 
its antidepressant effect. AD patients on an AChEI, however, may 
experience depressive symptoms in both the mild and moderate stages 
of AD.[38] In these patients the depression appears in part to be coupled 
to the renewed insight afforded the patient by the drug, and is usually 
transient in nature. When it persists, treatment with an antidepressant 
is indicated. [38]
Avoid tricyclics in therapeutic doses on account of anticholinergic 
side-effects, and ECG QTc problems, especially when combined with 
other medication, e.g. antipsychotics. 
Dementia patients fare better on ‘sedating’ antidepressants such as 
citalopram (20 mg), sertraline (50 - 150 mg), mirtazapine (15 - 30 mg) 
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and agomelatine (25 - 50 mg) at night. Escitalopram (2.5 - 5 mg) and 
venlafaxine (75 - 225 mg) are given in the mornings. The latter should 
only be used as second-line treatment. Augmentation usually involves 
neuroleptics, while electroconvulsive therapy may only be effective 
during the prodromal phase of the disorder.
4.3.3 Antipsychotics
Table 5 outlines a treatment schedule for restlessness, psychotic 
symptoms, agitation and insomnia. Note that haloperidol (a potent 
antipsychotic, with little sedation, but prone to extrapyramidal 
side-effects) acts synergistically with chlorpromazine (a less potent 
antipsychotic, sedating, and prone to postural hypotension as side-
effect). The drugs in combination usually allow for a lower dose of 
either agent, with fewer side-effects, affording better tolerability and 
targeting of symptoms. Some caregivers prefer one drug only, an even 
lower dosage of either agent, or different timing. Good caregivers will 
experiment with different regimens, tell you what their AD patient 
needs, and should be accommodated, for at the end of the day it is they 
who have to live with the consequences.[10,38] 
When aggression, psychosis, resistance to care or restlessness is 
prominent, low-dose risperidone/haloperidol at 0.25/0.5 mg twice 
daily is the drug of choice. Reinforce the day-night cycle by adding 
a sedative antipsychotic such as quetiapine/chlorpromazine 25 - 50 
mg at night (Table 5).[10] Titrate up as indicated. For acute sedation 
1 - 2 mg lorazepam orally or intramuscularly is the drug of choice 
(Table 6).[10] 
Table 3: Description of cognitive enhancers. Adapted from Taylor et al.,[32] Ihl et al.[33] and Rossiter[34]
Name
Donepezil 
(Aricept)
Rivastigmine 
(Exelon)
Galantamin 
(Reminyl)
Memantine 
(Ebixa)
Derivative Piperidine Carbamate Tertiary alkaloid Amantidine
Therapeutic class Acetylcholinesterase 
inhibitors 
Acetylcholinesterase inhibitors Acetylcholinesterase 
inhibitors 
NMDA receptor antagonist
Therapeutic dose 5 - 10 mg at night 3 - 6 mg 2 x daily 16 - 24 mg daily 5 - 10 mg 2 x daily
Starting dose 5 mg at night 1.5 mg 2 x daily 8 mg daily 5 mg daily
Presentation 5 mg, 10 mg tablets 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules 8 mg, 16 mg, 24 mg CR 
capsules
10 mg tablets/oral drops
Interval between dose 
increases
4 weeks 4 weeks 4 weeks 1 week weighted mornings
Common adverse effects
(often transient)
Nausea, vomiting, 
diarrhoea, fatigue, 
insomnia, muscle 
cramps, anorexia, 
headache, vivid dreams 
Nausea, vomiting, diarrhoea, 
dizziness, anorexia, confusion, 
headache, somnolence, muscle 
cramps
Nausea, vomiting, 
diarrhoea, abdominal 
pain, anorexia, fatigue, 
dizziness, headache, 
somnolence
Confusion, dizziness, 
headache, tiredness, 
constipation 
Half-life (h) 70 12 7 - 8 60 - 100
Metabolism CYP 2D6
CYP 3A4
Non-hepatic CYP 2D6 Primarily non-hepatic
Drug-drug interactions Yes Interaction unlikely Yes Yes
NMDA = N-methyl-D-aspartate; CR = controlled release; CYP = cytochrome P.
Table 4. Approach to neuropsychiatric symptoms/behavioural and psychological symptoms of dementia. Adapted from 
Ames et al.[36] and Taylor et al.[34] 
Take a routine history (patient and key informants) focusing on mental state (including MMSE) and assess interpersonal and environmental factors. Key 
questions around symptoms exhibited, the circumstances under which they arose and management strategies utilised to date.
Exclude physical illness potentially precipitating NPS/BPSD, e.g. constipation, infection (e.g. urinary tract infections especially from dehydration) and pain.
Target the symptom requiring treatment.
Consider non-pharmacological methods.
Psycho-educate the patient (if they have the capacity) and family/caregiver.
Carry out a risk/benefit analysis prior to selecting medication. Ideally start with an AChEI or memantine prior to other psychotropic medication. Discuss 
the use and side-effect profile fully with patient/family/caregiver.
Titrate medication from a low starting dose and maintain the lowest dose possible for the shortest period of time necessary.
Review medication regularly, monitoring for compliance, efficacy and adverse events.
Ensure support and ongoing psycho-education, monitoring and dealing with problems as they arise. Create awareness of local support group.
NPS = neuropsychiatric symptoms; BPSD = behavioural and psychological symptoms of dementia; AChEi = acetylcholinesterase inhibitors.
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Ultimately, it is the treatment with which one is familiar and 
comfortable that works best. First-generation antipsychotics (FGAs) 
are probably as effective as second-generation antipsychotics (SGAs) 
but owing to their side-effect profile less well tolerated. As a rule 
of thumb, the ‘non-sedating’ antipsychotics have extrapyramidal 
symptoms as side-effects, the sedating antipsychotics have 
oversedation, hypotension and dizziness as their chief side-effect. 
There is no significant difference between treatment groups.[32,36] 
In 2004 increased mortality with antipsychotics in dementia raised 
warnings for risperidone and olanzapine, which over the years were 
extended to include all SGAs as well as FGAs. The risk of developing both 
serious and non-serious cerebrovascular adverse events (CVAEs) such as 
stroke and mortality increases threefold with the use of antipsychotics. To 
date the mechanism by which the risk of such CVAEs is raised remains 
obscure, and patients with poorly controlled cardiac arrhythmias, 
hypertension, diabetes and previous stroke are more at risk.[32] 
4.3.4 Other medications/strategies
4.3.4.1 Hypnotics
Avoid benzodiazepines on account of the frequent occurrences of 
daytime somnolence, emotional lability, confusion, incoordination, 
ataxia, memory impairment and incontinence. Implementation of 
measures of sleep hygiene is a prerequisite.
If medication is required for insomnia (preferably short-term) the 
following may be useful: 
• Benzodiazepine-related: zolpidem 5 mg or zopiclone 3.75 – 7.5 mg
• Antidepressants: Sedating agents such as citalopram 10 - 20 mg, 
trazodone 50 mg, mirtazapine 7.5 - 15 mg or agomelatine 25 mg at 
night.
• Neuroleptics: Sedating agents such as chlorpromazine 25 mg, 
olanzapine 2.5 mg (given at 17h00) or quetiapine 25 mg at night.
4.3.4.2 Mood stabilisers/anticonvulsants
Trials with anticonvulsants (carbamazepine, sodium valproate, 
lamotrigine, topiramate and gabapentin) have not produced 
convincing evidence upon which to advocate their routine use.[32]
4.3.4.3 Restless legs syndrome
Clonazepam 0.5 mg may be taken at bedtime. Failing this, a dopamine 
agonist may be indicated: pramipexole, 0.125 mg at night.
4.3.4.4 Hypersexuality
Cyproterone acetate 150 mg given every 2 - 4 weeks IMI is effective 
in combating paraphilia in non-dementing patients and those with 
dementia. Sexual disinhibition or hypersexuality will diminish within 
a few days. The strategy is to administer the medication for 6 months, 
then withhold treatment, and should symptoms re-emerge, another 3 
months of treatment is indicated. Very occasionally a further 3-month 
course may be necessary.[39]
4.3.4.5 Treatment-resistant psychoses and disruptive vocalisers
In these situations the clozapine/amisulpiride regimen (taking into 
account white cell count measurements) may be useful:
Initiate: clozapine
• Start with 12.5 mg (in very frail patients, prone to extrapyramidal 
side-effects) 
• Increase in 12.5 mg increments
• Start with 25 mg (in more robust patients)
• Increase in 25 mg increments
• If response is good, continue to near-intolerance level 
• Split dose with night-time weighting, then drop one level
• Total daily dose 125 - 300 mg
• Watch out for: sedation, hypotension, urinary incontinence and 
drooling
Add: amisulpiride
• Start with 50 mg
• Increase in 50 mg increments
• Split dose with night-time weighting
• Total daily dose 150 - 200 mg
• Watch out for sedation and dystonia
4.4 Non-pharmacological treatment
4.4.1 The patient
A complex interaction of biological, psychosocial and environmental 
factors contribute to the development of NPS in AD.[18] It is therefore 
important to observe for environmental triggers that influence 
behaviour, and get feedback from those around the patient,. This has 
led to the A-B-C approach, whereby Antecedents to the behaviour are 
noted, as well as details of the Behaviour (description, time, duration), 
and the Consequences. A disruptive patient may thus get much 
more attention from nursing staff than when they are quiet, which 
inadvertently reinforces their disruptive behaviour.[18] 
Environmental factors implicated in triggering NPS include excessive 
noise and stimulation, lack of daily structure and routine, confusing 
surroundings, excessive demands, loneliness and boredom. [18] Specific 
Table 5. Example of a neuroleptic regimen[10]
Haloperidol (Serenace)/risperidone (Risperdal) 0.5 mg/0.25 - 0.5 mg 
respectively twice daily. 
Increase the dose to 0.75 mg, 1.0 mg and 1.5 mg twice daily, if necessary, 
for daytime control. Wait a day or two between increases.
Together with:
Chlorpromazine (Largactil)/quetiapine (Seroquel) 25 mg at night
 Increase the dose to 50 mg, 75 mg and 100 mg at night, if 
necessary, for nocturnal control.
 Wait a day or two between increases.
Or: 
Olanzapine (Zyprexa) 2.5 - 5 mg at 17h00
Table 6. Psychotropics for acute sedation[10]
One of the following agents: 
Lorazepam (Ativan) 
1 - 2 mg po/IMI
0.5 - 1.5 mg IVI
Do not exceed 8 mg over 24 hours
Haloperidol (Serenace)
2.5 mg IMI/IVI
Do not exceed 10 mg over 24 hours
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non-pharmaceutical interventions that enjoy 
success are validation therapy, positive 
reinforcement, reminiscence therapy, reality 
orientation and creative diversions, among 
others. 
4.4.2 The caregiver
A most vital link in the pharmacotherapy and 
general care of AD is the caregiver. Caregivers 
are estimated to spend an average of 70 - 100 
hours per week on providing care. Caregivers 
utilise 45% more physician visits and 70% 
more prescription drugs than non-caregivers, 
and are more likely to be hospitalised. More 
than 50% of caregivers are at risk for clinical 
depression. [40,41] A recent study[42] showed that, 
in general, there was a six-fold risk of dementia 
in spouses of patients with dementia. Where 
husbands looked after spouses suffering from 
dementia the risk was twelve-fold. Judicious 
use of pharmacotherapy, therefore, not only 
alleviates the stress on the caregiver but also 
delays the institutionalisation of the AD patient. 
All caregivers should be referred to NPOs 
such as Dementia SA in the Western Cape 
and Alzheimer’s South Africa, elsewhere. 
Not only do these organisations assist in 
supporting caregivers and monitoring their 
well-being but they also explain how to care 
for the patient, provide support services – 
such as home help or respite care – wherever 
possible, provide counselling and medicolegal 
advice, and continually update the caregiver 
by means of newsletters, meetings or 
workshops, on the latest developments.
4.5 Preventative measures
It is estimated that the neurodegeneration 
in AD starts some 20 - 30 years before the 
appearance of the first clinical symptoms,[43] 
reflecting the need for earlier intervention while 
minimal brain damage has occurred. 
Note that the preventative measures 
mentioned below offer no benefit to people 
whose preclinical AD pathology is sufficiently 
advanced to produce dementia symptoms 
within very few years and especially once the 
dementia is clinically evident:
• Hormone replacement therapy (oestrogen 
with or without progesterone) is only 
effective if initiated at the time of menopause 
where a deficiency in female sex hormones 
has clearly been established.[44] 
• Vitamin E (≤400 IU) and C (400 mg) 
daily, preferably in combination.[45] Note 
that high-dose vitamin E (+400 IU daily) 
supplementation is associated with an 
increased mortality risk.[46] 
• Red wine (Bordeaux blend 250 - 500 ml 
daily). Ascribed to resveratrol and other 
aliphatic compounds.[47] 
• Non-steroidal anti-inflammatory drugs 
(NSAIDs). Conventional NSAIDs such 
as ibuprofen and voltaren[48] as well as 
naproxen used for as little as 2 - 3 years[49] 
may protect against AD.     
• Coffee. Consuming 3 - 5 cups of coffee (not 
decaffeinated or instant) a day decreases 
the risk of dementia/AD later in life.[50-52] 
Currently, there is interest in establishing 
a ‘risk score’ as early as midlife, similar to 
that of the risk of cardiovascular disease. 
It is hoped that these lifestyle changes, 
antioxidant supplementation and treatment 
of medical conditions may then decrease the 
risk of AD and other dementias in persons 
at risk.53 A diet rich in vitamins B, C, D 
and E (fruit and vegetables) and omega 3 
fatty acids (fish) and low in high trans-fat 
(processed foods) reflects in beneficial blood 
nutrient biomarker patterns influencing both 
cognitive function and brain volume.[54] 
• Physical exercise
• Weight reduction
• Control of hypertension
• Control of hypercholesterolaemia
• Dietary antioxidants
• Intellectual activity
• Leisure activities and hobbies
• Social networks
• Red wine
• Fish and other sources of omega 3
• Folate-rich food or low-dose vitamin B 
supplementation
5. Algorithm
Fig. 3 shows the treatment algorithm for 
dementia.
For further reading on the biological 
treatment of AD, please refer to Ihl et al.,[33] 
Rossiter[34] and Daoud.[55]
Yes
Yes
No
No
Concerns about memory
Initial assessment
No memory
Look at reason for concern
depression, anxiety or family history
Keep under review
Memory impairment
Delirium?
Treat cause Depression or anxiety disorder?
Conrm dementia
Reassess memory on
recovery
Treat depression/anxiety aggressively
Reassess memory on
recovery
Appropriate psychotropic or other
agent Residual
neuropsychiatric symptoms
Keeping under review
Stabilised
Non-pharmacological and 
pharmacological (cognitive
enhancers) interventions
Fig. 3. Algorithm for therapy of dementia (adapted from Daoud[55]).
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6. Summary points
• Treatment with antidementia medication combined with non-
pharmacological measures provides the most benefits in patients 
with dementia.
• Medication must be individualised taking into account the 
constellation of symptoms, the stage of the disease, the side-effect 
profile, and caregiver availability.
• Titrate medication from a low starting dose.
• Target daily doses of first-line antidementia medication are as 
follows: donezepil 10 mg, rivastigmine 12 mg, galantamine 24 mg, 
and memantine 20 mg. This should, however, be guided by response 
and tolerability. These medications are effective in the symptomatic 
treatment of AD, VaD, DLB dementia, dementia in Parkinson’s 
disease and certain frontotemporal dementias.
• Patients should be closely monitored for the first month after 
commencing treatment.
• The most promising approach to VaD is secondary prevention of 
CvD by addressing its risk factors.
• Rule out underlying or coexisting medical conditions and 
psychosocial environmental factors in patients with behavioural, 
mood or anxiety symptoms. 
• In patients with depression, consider antidepressants that have 
more sedative effects, such as citalopram, sertraline, mirtazapine, 
and agomelatine. In view of the potential for QT prolongation, 
citalopram should not be used in doses greater than 20 mg per day 
in adults older than 60 years. 
• For hyperactivity or agitation, a low-dose first- or second-
generation antipsychotic medication may be used for a short period 
of time.
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